Belite Bio, Inc (BLTE)
BLTE price $153.81 +0.62 +0.41%
- Ticker
- BLTE
- Price
- $153.81
- Change
- +0.62 +0.41%
- Market cap
- $6.19B
- P/E
- -55.50
- Forward P/E
- 80.95
- Sector
- Healthcare
- Industry
- Biotechnology
- Stocklytics score
- 62
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is…